IL6 and ovarian cancer: The observation that PNA3 treatment also decreased IL-6 levels (Figs 3C and 4F,G) indicates that PNA3-targeting enhanced the response of ovarian cancer initiating cells to CDDP (Figs 3E,F and 4G).